Fespixon® is not approved by the U.S. FDA. This website is intended for international healthcare professionals outside the U.S. only.
FESPIXON® is the first topical macrophage-regulator clinically and scientifically proven to accelerate healing of diabetic foot ulcers. Its patented and evidence-based formula delivers fast, safe and effective results, even for the most challenging wounds.
FESPIXON® is indicated for prescription use (Rx)
Fespixon® is the first topical macrophage-regulator clinically and scientifically proven to accelerate healing of diabetic foot ulcers. Its patented and evidence-based formula delivers fast, safe and effective results, even for the most challenging wounds.
FESPIXON® is indicated for prescription use (Rx)
FESPIXON® demonstrates superior efficacy to standard care or current best care in treatment of diabetic foot ulcers in the international randomized controlled trial and real-world studies.
Fespixon® demonstrates superior efficacy to standard care or current best care in treatment of diabetic foot ulcers in the international randomized controlled trial and real-world studies.
FESPIXON® is backed by robust clinical evidence demonstrating significant improvements in complete healing rates and limb preservation. In both clinical and real-world studies, it delivers fast, effective results, even in high-risk patients.
Up to 80% complete healing observed in real-world studies, with many wounds closing within 2–6 weeks.
In an international randomized controlled trial (RCT) for diabetic foot ulcers (n=236), FESPIXON® achieved a 60.7% healing rate, outperforming standard care (p=0.0001).
FESPIXON® demonstrated significant reduction in amputation risk compared to the other advanced treatments.
Bonvadis® is backed by robust clinical evidence demonstrating significant improvements in complete healing rates and limb preservation. In both clinical and real-world studies, it delivers fast, effective results—even in high-risk patients.
Up to 80% complete healing observed in real-world studies, with many wounds closing within 2–6 weeks.
In a randomized controlled trial (RCT) for diabetic foot ulcers, Bonvadis® achieved a 60.7% healing rate, outperforming standard care (p=0.0001).
Significant reduction in amputation risk compared to the other advanced treatments.
FESPIXON® supports healing across the diabetic foot ulcer journey by modulating the expression of macrophages. It helps resolve chronic inflammation, promote epithelialization and support tissue remodeling. Clinical studies have demonstrated its efficacy for chronic, infected or non-healing wounds, including those in high-risk patients such as individuals on dialysis.
Bonvadis® supports healing across the full wound care continuum by creating an optimal moist microenvironment. It helps resolve chronic inflammation, promote epithelialization and support tissue remodeling with minimal scarring. It is especially effective for chronic, infected, or non-healing wounds, including those in high-risk patients such as individuals on dialysis.
Fespixon® naturally-derived formula is globally patented and clinically proven to accelerate healing of DFUs. It has excellent safety profile and non-immunogenic, suitable for long-term wound management.
Bonvadis® gentle, botanical-based formulation is naturally free from immune rejection, infection risk, and proteolytic degradation. Clinically proven for long-term and repeated use, Bonvadis® helps minimize scarring with no reported adverse effects.
Fespixon® is designed as an easy, effective wound care treatment for DFU. It requires no refrigeration and can be applied easily by a healthcare professional.
Fespixon® can also be integrated seamlessly in homecare setting for outpatient management, significantly lowering treatment burden for both patients and healthcare providers.
Bonvadis® is designed as easy, effective wound care treatment. It requires no refrigeration and can be applied easily by a healthcare professional. It is a cost-efficient solution for long-term care as it accelerates healing time.
Fespixon® delivers superior cost-effectiveness compared to advanced therapies such as skin substitutes. It can be used as a standalone treatment or in combination with other modalities, including standard dressings and negative pressure wound therapy (NPWT), overall accelerating wound healing and reducing long-term treatment costs.
Bonvadis® delivers superior cost-effectiveness compared to advanced therapies such as skin substitutes. It can be used as a standalone treatment or in combination with other modalities, including standard dressings, and negative pressure wound therapy (NPWT) , making it highly adaptable to diverse clinical settings and wound care protocols.
We’ve utilized the product basically and all the way through the algorithm. The product has just been superior to everything that we’ve been doing up to this point.
-Dr. Brock A. Liden/DPM, FABWH, FAPWCA
Diabetic Foot Ulcer
A 100 cm2 Tendon-exposed DFU
Diabetic Foot Ulcer
A Wagner grade 4 Ulcer Saved from Amputation
Post-surgical Wound
2nd Degree Burn
Bonvadis® may be used alongside other wound care treatments, as directed by your healthcare professional, based on clinical assessment. (e.g negative pressure wound therapy (NPWT), oxygen therapy and compression therapy)
Application of Bonvadis® to the affected area(s) should continue during any subsequent physical therapy treatments.
(1) The only wound bed optimization technology that demonstrates rapid granulation tissue growth in 7 days
(2) The etiology-driven technology for chronic wound healing via modulating wound environment
(3) Combination with systemic antibiotics in infected DFUs demonstrates superior effect
(4) Significant cost-saving evidence for treating DFUs
(5) Quality healing without hypertrophic scarring and improved mobility
